Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Propionic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 4/20 | 0.50 |
| ▸ | CA4 known ✓ | P22748 | 3/20 | 0.50 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL1332685 | 0.96 | — | — | |
| Propionic Acid SCHEMBL1331285 | 0.96 | — | — | |
| Propionic Acid SCHEMBL11213684 | 0.96 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL1332291 | 0.96 | — | — | |
| Propionic Acid SCHEMBL1332994 | 0.96 | — | — | |
| Propionic Acid SCHEMBL1331148 | 0.96 | — | — | |
| Propionic Acid SCHEMBL48908 | 0.96 | — | — | |
| Propionic Acid SCHEMBL15515998 | 0.96 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL594930 | 0.96 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Propionic Acid SCHEMBL1332719 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077364-A1 | NOVEL GEMINI SURFACTANTS AND THEIR USE | Empire Technology Development LLC (US) | 2016-10-12 | — | — | EP | claimed |
| WO-2015084304-A1 | NOVEL GEMINI SURFACTANTS AND THEIR USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-06-11 | — | — | WO | claimed |
| US-10106494-B2 | Gemini surfactant and their use | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2018-10-23 | — | — | US | disclosed |
| US-20160368863-A1 | NOVEL GEMINI SURFACTANT AND THEIR USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2016-12-22 | — | — | US | disclosed |
| EP-3077364-A1 | NOVEL GEMINI SURFACTANTS AND THEIR USE | Empire Technology Development LLC (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084304-A1 | NOVEL GEMINI SURFACTANTS AND THEIR USE | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106494-B2 | Gemini surfactant and their use | GEMIN4, GMNN, GEMIN5 | CA1 3323/4885CA4 4301/4885CA2 4245/4885 |
| US-20160368863-A1 | NOVEL GEMINI SURFACTANT AND THEIR USE | GEMIN4, GEMIN5, GMNN | CA1 3546/4885CA4 4441/4885CA2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.